BTIG Research Issues Positive Forecast for Innoviva (NASDAQ:INVA) Stock Price

Innoviva (NASDAQ:INVA - Get Free Report) had its target price lifted by research analysts at BTIG Research from $35.00 to $42.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the biotechnology company's stock. BTIG Research's price target would suggest a potential upside of 86.50% from the stock's current price.

Separately, Weiss Ratings reissued a "buy (b)" rating on shares of Innoviva in a report on Friday, March 27th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $36.20.

Innoviva Stock Performance

INVA opened at $22.52 on Thursday. Innoviva has a 12-month low of $16.52 and a 12-month high of $25.15. The company has a current ratio of 14.64, a quick ratio of 13.85 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $1.67 billion, a PE ratio of 7.38 and a beta of 0.38. The firm has a 50 day moving average of $22.98 and a two-hundred day moving average of $21.29.

Innoviva (NASDAQ:INVA - Get Free Report) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $1.94 EPS for the quarter, beating the consensus estimate of $0.34 by $1.60. The business had revenue of $114.61 million for the quarter, compared to the consensus estimate of $102.62 million. Innoviva had a net margin of 65.92% and a return on equity of 37.63%. On average, analysts anticipate that Innoviva will post 1.99 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Innoviva by 11.6% in the fourth quarter. Vanguard Group Inc. now owns 7,917,103 shares of the biotechnology company's stock valued at $158,263,000 after purchasing an additional 819,757 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Innoviva by 0.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,360,401 shares of the biotechnology company's stock worth $87,164,000 after buying an additional 30,048 shares during the last quarter. State Street Corp grew its holdings in Innoviva by 9.4% in the 4th quarter. State Street Corp now owns 2,796,820 shares of the biotechnology company's stock valued at $55,908,000 after buying an additional 239,848 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Innoviva by 38.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,358,633 shares of the biotechnology company's stock worth $43,045,000 after acquiring an additional 650,151 shares during the last quarter. Finally, American Century Companies Inc. increased its stake in shares of Innoviva by 13.8% in the 3rd quarter. American Century Companies Inc. now owns 2,351,006 shares of the biotechnology company's stock worth $42,906,000 after acquiring an additional 284,253 shares during the last quarter. 99.12% of the stock is owned by hedge funds and other institutional investors.

About Innoviva

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva's portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.